Place · Level 3
Folate
一碳单位搬运工 · DNA 合成的材料流 · 和 B12 共管甲基化
Story path
Chapter 1
Leafy B9
Leafy B9
The name folate comes from leaf. Dark leafy greens, legumes, asparagus, avocado, citrus, and animal liver are common sources.
There are two forms with different behavior: food folate is reduced and ~50–80% bioavailable; the folic acid in supplements is oxidized, more stable, and ~100% bioavailable on an empty stomach.
Guidelines unify measurement with DFE (dietary folate equivalents) because folic acid is more potent than natural folate. The conversion: 1 mcg DFE = 1 mcg food folate = 0.6 mcg folic acid (taken with food).
There are two forms with different behavior: food folate is reduced and ~50–80% bioavailable; the folic acid in supplements is oxidized, more stable, and ~100% bioavailable on an empty stomach.
Guidelines unify measurement with DFE (dietary folate equivalents) because folic acid is more potent than natural folate. The conversion: 1 mcg DFE = 1 mcg food folate = 0.6 mcg folic acid (taken with food).
How to read DFE labels
'Folate' on a nutrition label can be three different things with very different equivalence factors — one of the most easily misread items on a panel.Three forms:
Food folate (natural): multiple polyglutamate forms; gut must remove extra glutamates before absorption, ~50% bioavailableFolic acid (synthetic, used in fortified foods and supplements): oxidized monomer, easily absorbed, ~100% bioavailable fasted, ~85% with food5-MTHF (methyl folate, 'active folate' supplement): enters circulation directly as the active form, bypassing the DHFR reduction step, ~85% bioavailable
DFE (Dietary Folate Equivalents) conversions:
1 µg DFE = 1 µg food folate1 µg DFE = 0.6 µg folic acid with food1 µg DFE = 0.5 µg folic acid fasted
So '400 µg folic acid with food during pregnancy' equals 400 / 0.6 = 666 µg DFE, well above the number on the label.
RDA:
Adult 400 µg DFE/dayPregnancy 600 µg DFE/dayLactation 500 µg DFE/dayWomen planning pregnancy: starting at least 1 month before conception, ≥ 400 µg folic acid plus food folate
On MTHFR TT homozygotes plus preconception: some clinicians suggest switching to 5-MTHF instead of folic acid, since the latter needs DHFR reduction to enter circulation and TT individuals have lower enzyme activity. Evidence is mixed — most TT individuals carry healthy pregnancies on plain folic acid; 5-MTHF is closer to insurance than necessity.
Chapter 2
One-carbon carrier
One-carbon carrier
Folate's core job is shuttling one-carbon units: methyl (CH₃), methylene (CH₂), formyl (CHO) — small carbon fragments.
These one-carbon units are sent to two destinations:
DNA base synthesis: de novo synthesis of thymidylate (TMP) and purines requires the carbon fragments folate carriesMethylation cycle: 5-methyl-THF donates its methyl group to homocysteine → resynthesizes methionine → S-adenosylmethionine: The body's main methyl-group donor — it tags DNA, neurotransmitters, and more with methyl groups. (the universal methyl donor)
That's why rapidly dividing tissues are most vulnerable to folate deficiency: bone marrow hematopoiesis, fetal neural tube, intestinal mucosa all renew quickly and need a steady DNA-precursor supply. When folate is deficient, DNA synthesis stalls — cells enlarge but cannot divide. That's the cytologic basis of megaloblastic anemia.
These one-carbon units are sent to two destinations:
DNA base synthesis: de novo synthesis of thymidylate (TMP) and purines requires the carbon fragments folate carriesMethylation cycle: 5-methyl-THF donates its methyl group to homocysteine → resynthesizes methionine → S-adenosylmethionine: The body's main methyl-group donor — it tags DNA, neurotransmitters, and more with methyl groups. (the universal methyl donor)
That's why rapidly dividing tissues are most vulnerable to folate deficiency: bone marrow hematopoiesis, fetal neural tube, intestinal mucosa all renew quickly and need a steady DNA-precursor supply. When folate is deficient, DNA synthesis stalls — cells enlarge but cannot divide. That's the cytologic basis of megaloblastic anemia.
Methotrexate & folate
Methotrexate (MTX) is the most important clinical folate antagonist — both a chemotherapy drug and a first-line treatment for rheumatoid arthritis, psoriasis, and IBD.Mechanistically, MTX is structurally similar to folate and competitively inhibits DHFR (dihydrofolate reductase), preventing THF regeneration and blocking DNA synthesis (especially TMP). Rapidly dividing cancer cells and activated immune cells are hit hardest.
It has two use patterns with completely different clinical contexts.
High-dose chemotherapy:
Used for acute lymphoblastic leukemia (ALL), osteosarcoma, some lymphomasDose 500–5000 mg/m² (far above the 15–25 mg/week of rheumatology use)24–48 h after MTX, IV leucovorin (folinic acid) is typically given as 'rescue' to protect normal cells from DNA synthesis blockadeTiming or dose errors can be fatal
Low-dose anti-inflammatory:
Used for rheumatoid arthritis, psoriasis, psoriatic arthritis, IBDDose 7.5–25 mg/week (oral or subcutaneous)Usually paired with daily folic acid (1 mg/day or 5 mg once a week) to reduce nausea, mouth ulcers, elevated liver enzymes, and bone marrow suppression. RCTs repeatedly confirm this pairing doesn't reduce MTX efficacy.
Practical points: take folic acid as prescribed (not folinic acid, unless your physician specifies); don't self-escalate, or you'll blunt MTX's anti-inflammatory effect; pregnancy is an absolute contraindication — MTX is teratogenic and raises miscarriage risk, typically requiring at least 3 months off before trying to conceive.
This is a clear example that 'more folate is not always better': in certain drug and disease contexts, different folate forms carry completely different clinical meaning.
Chapter 3
MTHFR genetics
MTHFR genetics
MTHFR (methylenetetrahydrofolate reductase) is a key enzyme in the folate cycle, reducing 5,10-methylene-THF to 5-methyl-THF (the active form for the methylation cycle).
C677T variant: globally ~10–15% are TT homozygotes and ~40–50% are CT heterozygotes. TT homozygotes have MTHFR activity reduced by ~70%. When folate intake is inadequate, 5-methyl-THF production drops → methylation efficiency falls → homocysteine rises.
Real-world impact:
Most TT homozygotes with adequate folic acid intake have no clinically meaningful consequencesRisk is amplified when folate intake is marginalSome studies suggest TT individuals respond more directly to methylfolate (5-MTHF) supplements
Note: the MTHFR variant is not a 'disease gene'. The absolute disease risk in TT homozygotes still depends on overall folate status. The clinical significance of MTHFR testing is heavily overstated in the marketplace.
C677T variant: globally ~10–15% are TT homozygotes and ~40–50% are CT heterozygotes. TT homozygotes have MTHFR activity reduced by ~70%. When folate intake is inadequate, 5-methyl-THF production drops → methylation efficiency falls → homocysteine rises.
Real-world impact:
Most TT homozygotes with adequate folic acid intake have no clinically meaningful consequencesRisk is amplified when folate intake is marginalSome studies suggest TT individuals respond more directly to methylfolate (5-MTHF) supplements
Note: the MTHFR variant is not a 'disease gene'. The absolute disease risk in TT homozygotes still depends on overall folate status. The clinical significance of MTHFR testing is heavily overstated in the marketplace.
MTHFR test fatigue
'MTHFR testing' is one of the most over-hyped direct-to-consumer genetic tests. The gap between marketing pitches and medical consensus is wide.The direct-marketing pitch roughly says: 'You have an MTHFR mutation, your detox is impaired, you must use methylfolate plus various methylation supplements, avoid plain folic acid, and undergo detox protocols.' It bundles MTHFR with chronic fatigue, autism, depression, miscarriage, anxiety, and dementia into a personalized package costing 500–2000+ yuan.
Mainstream consensus (ACMG, American College of Medical Genetics, 2013, updated 2020) is far more restrained:
MTHFR C677T and A1298C are common polymorphisms, not 'disease genes'TT homozygotes are 10–15% of the population — carrier rate is highThe only established clinical association is that TT homozygotes with marginal folate intake show moderate Hcy elevation plus a slight increase in NTD riskEvidence for MTHFR links to miscarriage, autism, and depression is weak and inconsistentNot recommended as routine testing for infertility, depression, or cardiovascular evaluationNo need to avoid folic acid — for TT homozygotes, folic acid and 5-MTHF are equivalent in improving Hcy (Patanwala 2014 RCT)
The genuinely useful 'MTHFR intervention' is mundane: get folate intake to the RDA of 400 µg DFE/day (leafy greens + fortified foods + supplements as needed); ensure adequate B12 for synergistic methylation; don't smoke, limit alcohol, control glucose, exercise regularly — these factors matter far more than genotype.
On whether 5-MTHF supplementation is mandatory for TT homozygotes: it isn't. Folic acid also improves Hcy. 5-MTHF is more direct on the pathway (bypassing both DHFR and MTHFR), and 400–800 µg/day is sufficient if you choose to use it. The price is typically 2–3× higher; there's no need to pay more for a 'specialized formula'.
Summary: MTHFR is a real metabolic variant, but 'MTHFR-positive means I need a complex personalized supplement protocol' is an overreach. The vast majority of TT carriers do fine on a sensible diet plus plain folic acid.
Chapter 4
Locked with B12
Locked with B12
B12 is the cofactor for methionine synthase (MTR). Without B12, 5-methyl-THF cannot donate its methyl group to homocysteine, and folate gets stuck in this form — the methyl-folate trap.
The result is counterintuitive: folate looks abundant, but the THF forms cells need for DNA synthesis are depleted, so DNA synthesis still fails — both deficiencies present with a similar megaloblastic anemia.
The more important clinical trap: high-dose folic acid can correct the anemia caused by B12 deficiency, but cannot fix the neurologic damage. This may mask B12 deficiency, letting nerve injury progress silently under the appearance of 'corrected anemia'.
High-risk groups: long-term vegans, the elderly (reduced intrinsic factor), long-term PPI/H2-blocker users, long-term metformin users.
The result is counterintuitive: folate looks abundant, but the THF forms cells need for DNA synthesis are depleted, so DNA synthesis still fails — both deficiencies present with a similar megaloblastic anemia.
The more important clinical trap: high-dose folic acid can correct the anemia caused by B12 deficiency, but cannot fix the neurologic damage. This may mask B12 deficiency, letting nerve injury progress silently under the appearance of 'corrected anemia'.
High-risk groups: long-term vegans, the elderly (reduced intrinsic factor), long-term PPI/H2-blocker users, long-term metformin users.
Mandatory fortification debate
Global folic acid fortification policy is among the most successful public health interventions ever, and also one of the most contested.Around 80 countries mandate fortification: the US has required folic acid 140 µg per 100 g flour in grain products since 1998, and Canada, Chile, Brazil, Australia, Indonesia, and South Africa have followed. The goal is preventing neural tube defects (NTDs), since roughly half of pregnancies are unplanned and supplementation starting after conception is too late (the neural tube closes 21–28 days post-conception). The effect: NTD incidence has fallen 30–50% (Williams 2015 CDC long-term data).
Many countries don't fortify: most of Europe (UK, France, Germany, Nordics) worries about masking B12 deficiency and elderly neurologic damage, plus the unknown long-term impact of UMFA (unmetabolized folic acid). China doesn't mandate it, but prenatal care includes folic acid supplements. Japan doesn't fortify and recommends self-supplementation.
The controversy centers on three points.
First, 'masking B12': high folic acid intake can correct megaloblastic anemia, hiding the earliest sign of B12 deficiency, while the B12-related neurologic injury keeps progressing as dementia and neuropathy in the elderly. Some US surveys suggest undiagnosed B12 deficiency in the elderly may have risen post-fortification, but the data is mixed and the debate continues.
Second, the long-term unknown of UMFA. Large folic acid intake (cumulative > 200–400 µg/day) exceeds DHFR's reduction capacity, so unmetabolized folic acid enters the bloodstream directly. Animal studies suggest UMFA affects NK cell activity and may promote some tumor growth; long-term human effects remain unclear, but this is the main basis for Europe's cautious stance.
Third, the colon cancer double-edged effect: early folate exposure (in pregnancy and childhood) appears protective by reducing DNA damage; but in people with existing adenomas or precancerous lesions, high folate intake may accelerate progression (Cole 2007 JAMA). This is a clear case of 'dose plus timing' complexity.
A balanced practical approach: fortified foods plus dietary sources provide a safe, effective 400–600 µg DFE/day total; additional supplementation is reasonable mainly in preconception and early pregnancy, not for others without a diagnosed deficiency; elderly folate testing should include B12 testing and avoid high-dose folate alone; people with a colon cancer history or high risk should discuss folate intake strategy with their physician.
Chapter 5
Neural tube window
Neural tube window
Folate's strongest public health evidence is in preconception and early pregnancy. The neural tube closes within 21–28 days of conception — often before pregnancy is recognized.
Guidelines therefore stress: anyone who could become pregnant should ensure adequate folate starting at least 1 month before conception. The FDA's grain fortification requirement is based on exactly this timing logic.
Dose: general adult RDA 400 mcg DFE/day; preconception / pregnancy supplements typically contain 400–800 mcg folic acid; people with prior NTD-affected pregnancy or on anticonvulsants should use 4000 mcg/day under physician guidance (high-dose prevention protocol).
This isn't 'pregnancy supplement marketing' — it's a real developmental window limitation.
Guidelines therefore stress: anyone who could become pregnant should ensure adequate folate starting at least 1 month before conception. The FDA's grain fortification requirement is based on exactly this timing logic.
Dose: general adult RDA 400 mcg DFE/day; preconception / pregnancy supplements typically contain 400–800 mcg folic acid; people with prior NTD-affected pregnancy or on anticonvulsants should use 4000 mcg/day under physician guidance (high-dose prevention protocol).
This isn't 'pregnancy supplement marketing' — it's a real developmental window limitation.
Preconception + pregnancy roadmap
Below is a time-ordered roadmap for pregnancy folate, drawing on ACOG, WHO, and Chinese Obstetrics & Gynecology Society guidelines.Preconception (1–3 months before conception):
All women who could become pregnant: 400–800 µg folic acid/dayMaintain dietary base (leafy greens + legumes + fortified grains)Confirm adequate vitamin B12, especially for vegetarians
First trimester (0–12 weeks):
Continue 400–800 µg folic acid + food folateNeural tube closes 21–28 days post-conception — this is the most critical windowTypically continued through 12 weeks
Mid and late pregnancy (13–40 weeks):
RDA 600 µg DFE/day (roughly 400 µg folic acid + food)Most women meet this with a prenatal vitamin plus fortified foodsContinue adequate B12
Lactation:
RDA 500 µg DFE/dayBreast milk prioritizes folate to the infant; maternal stores are protected
Several high-risk groups typically need the 4–5 mg/day high-dose prevention protocol (about 10× routine dose):
Prior pregnancy affected by neural tube defect → next pregnancy 4 mg/day starting 1 month preconception through first trimesterPersonal or first-degree relative with NTD historyLong-term anticonvulsants (valproate, carbamazepine, phenytoin)Within 1–3 months of methotrexate discontinuationSevere obesity (BMI > 35), elevated NTD riskDiabetes, especially poorly controlledLong-term smoking or alcohol abuse, poor overall nutrition
When to stop supplementing: NTD risk passes after 12 weeks, but continuing through later pregnancy and lactation still benefits other folate-dependent developmental processes; return to routine RDA after weaning.
A few common misconceptions:
'Eating lots of spinach means I don't need to supplement' — food folate is only ~50% bioavailable, hard to reliably reach 600 µg from food alone'Start supplementing once I'm pregnant' — the 21-day window may have already passed'My periods are regular so I don't need preconception supplementation' — even with regular cycles, about half of pregnancies are unplanned; leaving safety margin is prudent
Chapter 6
Not more is better
Not more is better
Food folate is highly safe; the concern is long-term high-dose folic acid.
The adult folic acid UL is 1000 mcg/day, with two main concerns:
1. Masking B12 deficiency (see previous scene)
2. Elevated unmetabolized folic acid (UMFA): when large folic acid doses exceed DHFR's reduction capacity, unmetabolized folic acid enters circulation; long-term effects remain unclear
3. Some studies suggest high UMFA is associated with altered immune cell activity, but clinical significance remains unresolved
Practical advice: build a base of dark leafy greens plus legumes, use fortified grains as a complement, take supplements during pregnancy or under specific medical direction — and don't chase 'more is better'.
The adult folic acid UL is 1000 mcg/day, with two main concerns:
1. Masking B12 deficiency (see previous scene)
2. Elevated unmetabolized folic acid (UMFA): when large folic acid doses exceed DHFR's reduction capacity, unmetabolized folic acid enters circulation; long-term effects remain unclear
3. Some studies suggest high UMFA is associated with altered immune cell activity, but clinical significance remains unresolved
Practical advice: build a base of dark leafy greens plus legumes, use fortified grains as a complement, take supplements during pregnancy or under specific medical direction — and don't chase 'more is better'.
Natural vs synthetic
'Natural food folate vs synthetic folic acid' is a hot topic in the supplement market. Going through the evidence point by point:The three forms compared:
Food folate (multiple polyglutamate forms): from leafy greens, legumes, liver, fortified grains; gut must remove extra glutamates before absorption; ~50% bioavailable; safe at any doseFolic acid (synthetic pteroylglutamic acid): standard supplement form; absorbed intact in the gut then converted by DHFR and MTHFR to active 5-MTHF; ~85–100% bioavailable; UL 1000 µg/day; very high doses can produce UMFA5-MTHF (L-methylfolate, levomefolate): already in methylated form; bypasses DHFR and MTHFR conversion; ~85% bioavailable; typically 2–3× the price of folic acid
On whether 'folic acid is unnatural / harmful':
Arguments for avoiding it come down to three: UMFA's long-term effects are unknown (precautionary principle), MTHFR TT homozygotes have reduced conversion efficiency, and 'the body should align with nature' as a philosophical preference.
The counter-arguments are clear: folic acid fortification has been running for about 70 years across multiple generations without producing clear long-term harm; UMFA's clinical significance remains unestablished; TT homozygotes respond well to folic acid (Patanwala 2014); 5-MTHF's advantages remain largely theoretical, with clinical evidence comparable to folic acid.
Practical recommendations: for most people, folic acid is fully usable and inexpensive; 5-MTHF is fine if preferred but doesn't justify spending more; food folate should be the base, with supplements as a complement; what really should be avoided is chronic high-dose folic acid (> 1000 µg/day) without indication.
This is essentially a tension between personalized nutrition and public health: public health data supports folic acid fortification as having saved many lives; on an individual level, 5-MTHF is an option but not a necessity.